Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study

Rolof G. P. Gijtenbeek; V. Van Noort; J. G. J. V. Aerts; J. A. Staal-Van den Brekel; E. F. Smit; F. H. Krouwels; F. A. Wilschut; T. J. N. Hilterman; W. Timens; E. Schuuring; J. D. J. Janssen; M. Goosens; P. M. Van de Berg; A. J. De langen; J. A. Stigt; B. E. E. M. Van den Borne; H. J. M. Groen; W. H. Van Geffen; A. J. Van der Wekken

doi:10.1183/13993003.congress-2021.OA4324

Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study

Rolof G. P. Gijtenbeek, V. Van Noort, J. G. J. V. Aerts, J. A. Staal-Van den Brekel, E. F. Smit, F. H. Krouwels, F. A. Wilschut, T. J. N. Hilterman, W. Timens, E. Schuuring, J. D. J. Janssen, M. Goosens, P. M. Van de Berg, A. J. De langen, J. A. Stigt, B. E. E. M. Van den Borne, H. J. M. Groen, W. H. Van Geffen, A. J. Van der Wekken

Groningen Research Institute for Asthma and COPD

Onderzoeksoutput: Meeting Abstract › Academic

Originele taal-2	English
Aantal pagina's	3
Tijdschrift	European Respiratory Journal
Volume	58
DOI's	https://doi.org/10.1183/13993003.congress-2021.OA4324
Status	Published - 5-sep.-2021

Toegang tot document

10.1183/13993003.congress-2021.OA4324

Handle.net

Permanente koppeling

Citeer dit

Gijtenbeek, R. G. P., Van Noort, V., Aerts, J. G. J. V., Staal-Van den Brekel, J. A., Smit, E. F., Krouwels, F. H., Wilschut, F. A., Hilterman, T. J. N., Timens, W., Schuuring, E., Janssen, J. D. J., Goosens, M., Van de Berg, P. M., De langen, A. J., Stigt, J. A., Van den Borne, B. E. E. M., Groen, H. J. M., Van Geffen, W. H., & Van der Wekken, A. J. (2021). Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study. European Respiratory Journal, 58. https://doi.org/10.1183/13993003.congress-2021.OA4324

@article{84c991c74d34466381785ff17a57e8e2,

title = "Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study",

keywords = "Lung cancer - management, Lung cancer, Treatments",

author = "Gijtenbeek, {Rolof G. P.} and {Van Noort}, V. and Aerts, {J. G. J. V.} and {Staal-Van den Brekel}, {J. A.} and Smit, {E. F.} and Krouwels, {F. H.} and Wilschut, {F. A.} and Hilterman, {T. J. N.} and W. Timens and E. Schuuring and Janssen, {J. D. J.} and M. Goosens and {Van de Berg}, {P. M.} and {De langen}, {A. J.} and Stigt, {J. A.} and {Van den Borne}, {B. E. E. M.} and Groen, {H. J. M.} and {Van Geffen}, {W. H.} and {Van der Wekken}, {A. J.}",

year = "2021",

month = sep,

day = "5",

doi = "10.1183/13993003.congress-2021.OA4324",

language = "English",

volume = "58",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "EUROPEAN RESPIRATORY SOC JOURNALS LTD",

}

Gijtenbeek, RGP, Van Noort, V, Aerts, JGJV, Staal-Van den Brekel, JA, Smit, EF, Krouwels, FH, Wilschut, FA, Hilterman, TJN, Timens, W , Schuuring, E, Janssen, JDJ, Goosens, M, Van de Berg, PM, De langen, AJ, Stigt, JA, Van den Borne, BEEM, Groen, HJM, Van Geffen, WH & Van der Wekken, AJ 2021, 'Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study', European Respiratory Journal, vol. 58. https://doi.org/10.1183/13993003.congress-2021.OA4324

Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study. / Gijtenbeek, Rolof G. P.; Van Noort, V.; Aerts, J. G. J. V. et al.
In: European Respiratory Journal, Vol. 58, 05.09.2021.

Onderzoeksoutput: Meeting Abstract › Academic

TY - JOUR

T1 - Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study

AU - Gijtenbeek, Rolof G. P.

AU - Van Noort, V.

AU - Aerts, J. G. J. V.

AU - Staal-Van den Brekel, J. A.

AU - Smit, E. F.

AU - Krouwels, F. H.

AU - Wilschut, F. A.

AU - Hilterman, T. J. N.

AU - Timens, W.

AU - Schuuring, E.

AU - Janssen, J. D. J.

AU - Goosens, M.

AU - Van de Berg, P. M.

AU - De langen, A. J.

AU - Stigt, J. A.

AU - Van den Borne, B. E. E. M.

AU - Groen, H. J. M.

AU - Van Geffen, W. H.

AU - Van der Wekken, A. J.

PY - 2021/9/5

Y1 - 2021/9/5

KW - Lung cancer - management

KW - Lung cancer

KW - Treatments

U2 - 10.1183/13993003.congress-2021.OA4324

DO - 10.1183/13993003.congress-2021.OA4324

M3 - Meeting Abstract

SN - 0903-1936

VL - 58

JO - European Respiratory Journal

JF - European Respiratory Journal

ER -

Gijtenbeek RGP, Van Noort V, Aerts JGJV, Staal-Van den Brekel JA, Smit EF, Krouwels FH et al. Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study. European Respiratory Journal. 2021 sep. 5;58. doi: 10.1183/13993003.congress-2021.OA4324